n.a. (ZLCS)

5.39
0.00 (0.00)
NASDAQ
Prev Close 5.39
Open 5.60
Day Low/High 5.26 / 5.60
52 Wk Low/High 3.78 / 16.90
Volume 177.07K
Exchange NASDAQ
P/E Ratio 0.34
Div & Yield N.A. (N.A)
Zalicus Initiates Phase 1b Clinical Study Of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, For The Treatment Of Pain

Zalicus Initiates Phase 1b Clinical Study Of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, For The Treatment Of Pain

Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study ...

Zalicus To Present At The Rodman & Renshaw 15th Annual Global Investment Conference

Zalicus To Present At The Rodman & Renshaw 15th Annual Global Investment Conference

Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the Rodman...

Zalicus Completes Patient Enrollment In Two Phase 2 Clinical Studies Of Z160 For Chronic Neuropathic Pain

Zalicus Completes Patient Enrollment In Two Phase 2 Clinical Studies Of Z160 For Chronic Neuropathic Pain

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has completed patient enrollment in two ...

Zalicus Reports Financial Results For The Second Quarter 2013

Zalicus Reports Financial Results For The Second Quarter 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the second quarter ended June...

Zalicus Publishes Data On Selective Estrogen Receptor Modulators For The Treatment Of Infectious Disease

Zalicus Publishes Data On Selective Estrogen Receptor Modulators For The Treatment Of Infectious Disease

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has published preclinical data in Science Translational Medicine showing the beneficial effects of applying the Zalicus combination high-throughput ...

Zalicus Presents Data Demonstrating Advantages Of State-Dependent Ion Channel Screening

Zalicus Presents Data Demonstrating Advantages Of State-Dependent Ion Channel Screening

Zalicus Inc. (Nasdaq Global Market: ZLCS) today announced that preclinical data showing the advantages of applying Zalicus’s state dependent screening approach to identify novel calcium channel blockers for the...

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2012

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2012

Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ...

Zalicus Granted Composition-of-Matter Patent For Z944

Zalicus Granted Composition-of-Matter Patent For Z944

Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.

Zalicus To Present At The 2013 BIO CEO & Investor Conference

Zalicus To Present At The 2013 BIO CEO & Investor Conference

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the 2013 BIO CEO & ...

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Zalicus Initiates The Second Of Two Phase 2a Studies With Z160

Zalicus Initiates The Second Of Two Phase 2a Studies With Z160

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated the second of two Phase 2a clinical studies...

Zalicus To Present At The Oppenheimer 23rd Annual Healthcare Conference

Zalicus To Present At The Oppenheimer 23rd Annual Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the Oppenheimer 23 rd ...

Zalicus’ Z160 For Chronic Neuropathic Pain Selected As A Top 10 Project To Watch

Zalicus’ Z160 For Chronic Neuropathic Pain Selected As A Top 10 Project To Watch

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Z160, its first-in-class, oral, state-dependent, ...

Zalicus Reports Financial Results For The Third Quarter 2012

Zalicus Reports Financial Results For The Third Quarter 2012

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the third quarter ended September 30, 2012.

Acadia Pharma Selling Stock Ahead of Key Study Results

Acadia Pharma Selling Stock Ahead of Key Study Results

Acadia isn't desperate for cash so why sell stock before the pimavanserin study results?

Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin (FOV1101)

Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin (FOV1101)

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Sanofi provided an update on the development status of ...

Zalicus Reports Top Line Phase 2b Trial Results With Synavive In Rheumatoid Arthritis

Zalicus Reports Top Line Phase 2b Trial Results With Synavive In Rheumatoid Arthritis

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its ...

Zalicus Initiates The First Of Two Phase 2a Studies With Z160, A First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, For The Treatment Of Chronic Neuropathic Pain

Zalicus Initiates The First Of Two Phase 2a Studies With Z160, A First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, For The Treatment Of Chronic Neuropathic Pain

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the ...

8 Stocks Under $10 Making Big Moves

8 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Zalicus Announces FDA Approval Of 32mg Dose Strength Of EXALGO®

Zalicus Announces FDA Approval Of 32mg Dose Strength Of EXALGO®

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Zalicus To Present At The 2012 Wedbush PacGrow Lifesciences Management Access Conference

Zalicus To Present At The 2012 Wedbush PacGrow Lifesciences Management Access Conference

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that Zalicus management ...

Zalicus Reports Financial Results For The Second Quarter 2012

Zalicus Reports Financial Results For The Second Quarter 2012

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the second quarter ended June 30, 2012.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon Pharma: Rayos FDA Approval Thursday Seems Likely

Horizon will sell Rayos as a morning pain relief for patients with rheumatoid arthritis.

Biotech Stock Mailbag: Zalicus, Amarin

Biotech Stock Mailbag: Zalicus, Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Zalicus Initiates Phase 1 Multiple Ascending Dose Study With Z944, A Novel, Oral T-Type Calcium Channel Blocker

Zalicus Initiates Phase 1 Multiple Ascending Dose Study With Z944, A Novel, Oral T-Type Calcium Channel Blocker

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is has initiated a ...

Zalicus To Present At The 2012 JMP Securities Healthcare Conference

Zalicus To Present At The 2012 JMP Securities Healthcare Conference

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that Zalicus management will...

Zalicus Successfully Completes Phase 1 Single Ascending Dose Study With Z944 , A Novel, Oral T-Type Calcium Channel Blocker

Zalicus Successfully Completes Phase 1 Single Ascending Dose Study With Z944 , A Novel, Oral T-Type Calcium Channel Blocker

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is has ...

7 Stocks Under $10 Streaking Higher

7 Stocks Under $10 Streaking Higher

Pharma stocks dominate this list of stocks making sharp gains in recent sessions.